{"id":"W4200317891","doi":"10.1038/s41591-021-01538-9","title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Stanford Cancer Institute; National Cancer Institute; Scheme for Promotion of Academic and Research Collaboration; Constellation Pharmaceuticals; National Center for Advancing Translational Sciences; Agios Pharmaceuticals; NIH Blueprint for Neuroscience Research; Astellas Pharma; Gilead Sciences; ARUP Laboratories; Celgene; Sierra Oncology; Incyte; CTI Biopharma; National Heart, Lung, and Blood Institute; Pfizer; Amgen; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Systemic mastocytosis; Medicine; Nausea; Adverse effect; Gastroenterology; Internal medicine; Anemia; Phases of clinical research; Rash; Anaphylaxis; Diarrhea; Clinical trial; Immunology; Allergy; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009991218,0.0006993738,0.0009362423,0.0001556957,0.0001912576,0.0005926405,0.0003646034,0.0008516918,0.002351516],"category_scores_gemma":[0.0005862206,0.0001742897,0.0007046702,0.0001313209,0.0003503586,0.0004764464,0.0002322402,0.001499322,0.0004262946],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000437903,"about_ca_system_score_gemma":0.0003642584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002229104,"about_ca_topic_score_gemma":0.0007414009,"domain_scores_codex":[0.9997342,0.000140234,0.00001030195,0.00004159971,0.00003309986,0.00004053994],"domain_scores_gemma":[0.9997348,0.00006864467,0.00007937627,0.00001575523,0.00001783866,0.00008356999],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6226402,0.016067,0.0145535,0.002652403,0.002439719,0.0008635912,0.0004254033,0.006332516,0.06746337,0.001158714,0.01801355,0.24739],"study_design_scores_gemma":[0.6813954,0.2463109,0.04307596,0.0001618648,0.001195352,0.001846078,0.0001024969,0.005959814,0.007936747,0.001236324,0.01070534,0.00007370886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898372,0.00493775,0.0003160909,0.0006075419,0.00007432977,0.0005906296,0.0009984375,0.00009133993,0.002546723],"genre_scores_gemma":[0.9936779,0.001448047,0.0005295605,0.000528309,0.00009622039,0.0004932115,0.001411445,0.00001313925,0.001802237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002351516,"threshold_uncertainty_score":0.007866621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01102758964833315,"score_gpt":0.2781469277042364,"score_spread":0.2671193380559032,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}